These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 26099427)
41. DEX implant intravitreal injection, sustained intraocular hypertension, and steroid-induced glaucoma in patients with no risk factors. Rezkallah A; Kodjikian L; Malclès A; Dot C Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):219-220. PubMed ID: 28801709 [No Abstract] [Full Text] [Related]
42. Association of OCT angle recess width with IOP response after intravitreal triamcinolone injection. Singer MA; Groth SL; Sponsel WE; Herro A; Pollard J; Cohen SR; Cohen JH Retina; 2013 Feb; 33(2):282-6. PubMed ID: 22846803 [TBL] [Abstract][Full Text] [Related]
43. Laser trabeculoplasty. Lau LI; Liu CJ; Chen SJ; Ko YC; Lee FL; Hsu WM Ophthalmology; 2007 Sep; 114(9):1790. PubMed ID: 17822985 [No Abstract] [Full Text] [Related]
44. OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION OVER 3 TREATMENT ROUNDS. Reid GA; Sahota DS; Sarhan M Retina; 2015 Aug; 35(8):1647-55. PubMed ID: 25932545 [TBL] [Abstract][Full Text] [Related]
45. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Maia M; Farah ME; Belfort RN; Penha FM; Lima Filho AA; Aggio FB; Belfort R Br J Ophthalmol; 2007 Sep; 91(9):1122-4. PubMed ID: 17383993 [TBL] [Abstract][Full Text] [Related]
55. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Ding X; Li J; Hu X; Yu S; Pan J; Tang S Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319 [TBL] [Abstract][Full Text] [Related]
56. Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation. Sadiq MA; Agarwal A; Soliman MK; Hanout M; Sarwar S; Do DV; Nguyen QD Expert Opin Drug Saf; 2015 Jul; 14(7):1147-56. PubMed ID: 25994877 [TBL] [Abstract][Full Text] [Related]
57. INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Storey PP; Ho V; Yeh S; Reddy S; Fang-Yen NH; Pequignot E; Leiby BE; Fineman M; Garg S; Hubbard GB; Hsu J Retina; 2015 Oct; 35(10):1992-2000. PubMed ID: 26035396 [TBL] [Abstract][Full Text] [Related]
58. [Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide]. Jonas JB; Kreissig I; Degenring RF Klin Monbl Augenheilkd; 2003 Jun; 220(6):384-90. PubMed ID: 12830391 [TBL] [Abstract][Full Text] [Related]
59. Update of intravitreal steroids for the treatment of diabetic macular edema. Bandello F; Preziosa C; Querques G; Lattanzio R Ophthalmic Res; 2014; 52(2):89-96. PubMed ID: 25195600 [TBL] [Abstract][Full Text] [Related]
60. Locally administered ocular corticosteroids: benefits and risks. McGhee CN; Dean S; Danesh-Meyer H Drug Saf; 2002; 25(1):33-55. PubMed ID: 11820911 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]